-+ 0.00%
-+ 0.00%
-+ 0.00%
BioVersys, GSK's Tuberculosis Drug Shows Early Bactericidal Activity in Phase 2a Trial
Share
Listen to the news
01:58 AM EST, 11/20/2026 (MT Newswires) -- BioVersys (BIOV.SW) and GSK's (GSK.L) alpibectir combined with ethionamide demonstrated early bactericidal activity at all doses against drug-sensitive pulmonary tuberculosis in the 14-day phase 2a Enable study. The companies are collaborating in developing the combination treatment, known as AlpE, for pulmonary tuberculosis and tuberculosis meningitis, according to a Friday release. The study assessed a 45-milligram dose of alpibectir combined with either 125 mg or 250 mg of ethionamide in newly diagnosed patients. AlpE was evaluated both alone and in combination with rifampicin, pyrazinamide, and ethambutol in the Enable trial. A separate phase 2b trial called Step2C is assessing AlpE plus rifampicin, pyrazinamide, and ethambutol to assess its activity during the first two months of treatment. The study is underway in six African countries through the European Union's IMI2 Unite4TB project.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending